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A collaborative Canadian–United Kingdom evaluation of an immunohistochemistry
protocol to diagnose bovine spongiform encephalopathy
Lisa Manning, Katherine I. O’Rourke, Donald P. Knowles, Sarah A. Marsh, Yvonne I. Spencer,
Estella Moffat, Gerald A. H. Wells, Stefanie Czub1
Abstract. Collaboration was established in 2001 to evaluate a commercially available immunohistochem-
istry assay kit for the detection of bovine spongiform encephalopathy (BSE) disease–associated prion protein
in formic acid–treated formalin-fixed samples of bovine brain. The kit protocol was evaluated at the National
Centre for Foreign Animal Diseases (Winnipeg, Canada) and the Veterinary Laboratories Agency
(Weybridge, U.K.). The U.K. laboratory provided paraffin-embedded blocks of brainstem (medulla
oblongata at the level of the obex) from 100 positive cases defined by clinical signs and histopathology,
and 100 clinically suspect but BSE-negative samples defined by histopathology and immunohistochemistry
with anti-PrP monoclonal antibody R145. The Canadian laboratory provided 400 blocks from surveillance
cases defined as clinically suspect but negative by histopathology and immunohistochemistry with anti-PrP
antibody 6H4. Consecutive sections from each block were cut and coded. Each set of 600 slides was
immunolabeled and read in each laboratory. Evaluation parameters included estimates of diagnostic
sensitivity and specificity and reproducibility of the results. The kit performed with 100% sensitivity,
specificity, and reproducibility in spite of minor differences between the laboratories in brain sample areas,
fixation and processing, and in the immunolabeling protocol. Although enzyme linked immunosorbent
assays are widely used in high throughput surveillance programs, standardized protocols and reagents for
manual immunohistochemistry provide a useful adjunct to surveillance efforts, particularly in laboratories
testing small numbers of samples or using immunohistochemistry for confirmation and characterization of
BSE cases.
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Bovine spongiform encephalopathy (BSE) is a fatal
neurological disease of adult cattle that was first
recognized in Great Britain in 1986,16 and is one of the
subacute spongiform encephalopathies associated with
unconventional transmissible agents or prions.9 The
agent of BSE is considered the cause of variant
Creutzfeldt–Jakob disease (vCJD) in humans.2,4,12 The
rapid and accurate diagnosis of BSE is therefore of
critical importance to control measures for human and
animal health protection. When BSE surveillance was
implemented in 1992 in Canada, it was based on testing
mature cattle with clinical signs compatible with BSE
collected at provincial and federally inspected abattoirs,
from rabies-negative submissions, and from private
practitioners’ submissions. At the initiation of the
current study (2001), the U.K. BSE surveillance program
comprised passive surveillance of all cattle presenting
with clinical signs compatible with BSE, irrespective of
age, together with active surveillance that targeted all
cattle aged 30 months or over at death or slaughter
(fallen animals, on-farm casualties, and healthy slaugh-
tered). The surveillance program later included cattle
aged 24–30 months slaughtered for human consumption
but presenting as casualty animals or as animals
segregated at antemortem inspection as unfit. The
principal diagnostic approach for confirmation of BSE
was originally neuropathological examination for mor-
phological changes of spongiform encephalopathy.18
After recognition of the diagnostic importance of the
disease-associated form of the prion protein (PrPSc),
immunochemical methods using polyclonal or monoclo-
nal antibodies became standard approaches. For screen-
ing purposes these have evolved principally as high
throughput ELISA or Western blot formats, but
immunohistochemistry (IHC) provides a confirmatory
and complementary approach that characterizes PrPSc
distribution in brain to inform on disease phenotype.
Because the antibodies used for IHC cannot distinguish
between the cellular form of prion protein (PrPC) and
PrPSc, demonstration of disease-specific immunolabeling
is critically dependent on epitope demasking pretreat-
ments and on the pattern of antibody binding. For this
reason, it is important that the application and interpre-
tation of PrP IHC for BSE diagnosis includes an
understanding of the disease-specific topography and
cellular patterns of the immunolabelling under defined
assay conditions. In this study, the performance of a
commercially available IHC assaya for the disease-
associated prion protein in formalin-fixed tissue was
assessed in an international collaboration between the
National Centre for Foreign Animal Diseases (NCFAD;
From the National Centre for Foreign Animal Disease,
Winnipeg, Manitoba, Canada (Manning, Moffat, Czub), the U.S.
Department of Agriculture, Agricultural Research Service, Animal
Disease Research Unit, Pullman, WA (O’Rourke, Knowles), and
the Veterinary Laboratories Agency, New Haw, Addlestone,
Surrey, United Kingdom (Marsh, Spencer, Wells).
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CFIA, Winnipeg, Manitoba, Canada) and the Veterinary
Laboratories Agency (VLA; Weybridge, U.K.).
Samples of brain were collected over a 3-year period
(1998–2001) from cattle that exhibited neurological signs
at the time of slaughter or death. The diagnosis of all
cases included in this evaluation was based initially on
histological examination in the laboratory of origin. The
study included 100 cases considered BSE positive and 500
cases considered BSE negative. Positive cases demon-
strated histological evidence of spongiform changes
suggestive of BSE.18 The negative cases showed no
histologic evidence of spongiform encephalopathy and
no evidence of PrP-Sc when screened by immunohisto-
chemistry using MAb R145 (U.K. samples), a C-terminal
specific anti-PrP rat monoclonal antibody produced at
the VLA and raised against a bovine PrP peptide
sequence, residues 221–23315 or 6H4 (Canadian samples),
a murine monoclonal antibody raised against recombi-
nant bovine PrP and recognizing an epitope correspond-
ing to residues 156–164.6 Four hundred of the 500
negative samples were provided by NCFAD and 100 by
the VLA. All VLA samples represented the medulla
oblongata at the level of the obex. Of the 400 Canadian
samples, 35% were from the medulla at obex, 46% from
the medulla oblongata (nonobex), and the remaining 19%
were from other areas of the brain, including the
cerebellum. Samples were fixed and processed with minor
protocol differences between the NCFAD and VLA
laboratories, including fixation (10% neutral buffered
formalin overnight vs. 10% formol saline for 48 hr),
formic acid decontamination (2 hr vs. 1 hr), and embed-
ding medium (paraffinb or paraffin/plasticc). Four con-
secutive 5-mm sections from each block were mounted on
positively chargedd or treatede slides. Sections were coded
and exchanged between laboratories. Each laboratory
immunolabeled 1 set of 600 slides. All test kits were from
the same lot number and were supplied to each laboratory
by the manufacturer. The kit includes: a citrate buffer for
antigen retrieval by hydrated autoclaving,3 a proprietary
proteinase K (PK) reagent of undisclosed concentration,
primary monoclonal antibody F99/97.6.18 (a murine
IgG1 binding the epitope QYQRES, residues 220–225 of
the bovine PrP 5-octapeptide repeat molecule), antibody
diluent, antimouse–IgG–biotinylated secondary anti-
body, peroxidase-labeled streptavidin, and diaminoben-
zidine (DAB) as the substrate-chromogen. Each labora-
tory independently selected a single BSE case as a positive
control and a single non-BSE case as a negative control;
both controls were included in each run with 38 test
samples. Both laboratories immunolabeled the sections
using the same generic protocol, including pretreatment
with 3% (v/v) hydrogen peroxide in methanol to quench
endogenous peroxidase, antigen retrieval with acid
(undiluted 98% formic acid) for 5 min followed by 3
rinses with Tris buffered saline (TBS, pH 7.6) and
hydrated autoclaving (121uC for 20 min with the kit-
supplied citrate buffer). Slides were cooled, placed onto
facing plastic coverplates,f which provide a constant 100-
ml volume incubation chamber at the slide surface and a
2-ml reservoir above the slide for wash solution, and
transferred to a slide rackg designed to hold the assembly
vertically. Care was taken to remove air bubbles from the
assembly before application of reagents. Wash bufferh
was added to the reservoir and the sections were washed
by gravity flow of the solution. The kit-supplied PK
solution was added to the sections and incubated for 60
(VLA) or 90 (NCFAD) sec. Preliminary optimization
assays demonstrated that this step was time and temper-
ature dependent and performed most reliably if the
solution was removed from the refrigerator within 5–
10 min of use. The PK pretreatment caused partial
digestion of the tissue sections in some cases, although
this did not affect the final observations. Sections were
immunolabeled with sequential 10-min incubations at
room temperature with primary antibody at 1 or 10 mg/
ml, antimouse–IgG–biotin, and streptavidin–horseradish
peroxidase complex with intervening wash buffer rinses.
Five hundred microliters of DAB was added as the
enzyme substrate for 3–5 min (endpoint determined
macroscopically by NCFAD) or 10 min (standardized
by VLA). Deionized water was added and the coverplates
were removed. The slides were washed for 2 min in
running tap water, counterstained with Mayer’s hema-
toxylin, and blued in Scott’s Tap Wateri (NCFAD) or tap
water (VLA). After thoroughly washing in running tap
water for 4 min, the slides were dehydrated and placed
into xylene, then permanently mounted with mounting
media.
Two pathologists and 2 technicians evaluated each
coded slide using brightfield light microscopy. Samples
were considered positive if there was evidence of
chromogen deposits conforming to disease-associated
patterns of labeling17,18 in the dorsal nucleus of the
vagus nerve and the solitary tract nucleus, the regions
previously described as target areas for PrPSc accumu-
lation.18 Disease-specific labeling in samples immuno-
labeled with this protocol was as described previously
for BSE using other antibodies3,17,18 and corresponds to
some, but not all, forms of immunolabeling reported in
sheep with scrapie5,7,11 using polyclonal antisera and
other antibodies and in deer and elk with chronic
wasting disease,13,14 in a variety of manual and auto-
mated protocols. Multifocal particulate labeling (also
termed ‘‘punctate’’5 or ‘‘synapse-like’’18) predominated,
with variably sized, irregular particles distributed in a
random fashion through the neuropil without obvious
association with morphologically defined cells or struc-
tures. This labeling was most commonly evident as
separate fine particles but was sometimes also aggregat-
ed (Fig. 1A). Perineuronal labeling appeared similar to
the particulate labeling, but was clearly distributed in
close association with the neuronal membrane around
the perikaryon (Fig. 1B) and bordering neurites.
Throughout the sections there was glial-associated
labeling (Fig. 1C). The most obvious cell-associated
disease-specific labeling was a granular labeling of the
perikaryonal cytoplasm of neurons. This labeling was
either diffusely distributed throughout the cytoplasm or
localized, sometimes with a perinuclear location. La-
beled granules were usually round and variable in size
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(Fig. 1D). The specific labeling patterns observed in the
hypoglossal nucleus were predominantly neuronal with
some perineuronal particulate labeling. The dorsal
nucleus of the vagus nerve demonstrated mainly coarse
granular neuropil labeling and occasional intraneuronal
labeling. In the reticular formation, linear particulate
and coalescing labeling patterns were evident. Samples
were considered negative if no chromogen deposits were
Figure 1. Immunohistochemical detection of bovine spongiform encephalopathy in various bovine brainstem regions. A, reticular
formation: relatively sparse multifocal particulate labeling (red arrow). Particles vary in size and are sometimes aggregated (black
arrow). Immunohistochemistry (IHC). F99/97.6.1. Bar 5 20 mm. B, reticular formation: granular labeling of the cell membrane (arrow)
of a vacuolated neuron. IHC. F99/97.6.1. Bar 5 20 mm. C, neuropil (adjacent to dorsal vagal nucleus): glial associated labeling (arrow)
bordering a glial nucleus. IHC. F99/97.6.1. Bar 5 20 mm. D, hypoglossal nucleus: granular labeling of a neuronal perikaryon.
Cytoplasmic granules (arrow) are round and variable in size. IHC. F99/97.6.1. Bar 5 20 mm.
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observed or if the disease-associated patterns of labeling
were absent.
Results from both laboratories were tabulated at
NCFAD. The performance of each immunohistochem-
istry (IHC) run was monitored by using BSE-positive
control tissue sections and documented as 100%
repeatable within each laboratory. All 100 positive
and 500 negative cases were correctly identified by both
laboratories, yielding 100% sensitivity, specificity, and
reproducibility.19 These findings were derived in spite
of minor variation between the laboratories in neuro-
anatomic sample site selection, fixation and processing,
and immunolabeling protocols, as well as inherent
differences in local water supply and laboratory room
temperatures. The results obtained by the 2 national
reference laboratories confirm the robustness and
validity of these procedures for the detection of BSE
field cases. Subsequent to this study, mAb F99/97.6.1
was included in the panel of antibodies used in the
confirmatory IHC testing schedule for BSE diagnosis at
the NCFAD. Eight Canadian BSE cases and 2 U.S. BSE
cases were confirmed with this antibody, including
atypical BSE cases in the United States10 and Canada
(unpublished data). The availability of a standardized,
complete IHC kit for the detection of PrP is useful to
laboratories that perform primary screening and/or
confirmatory testing of small numbers of cattle by
manual IHC. The kit procedure is easily adapted to
automated staining systems1 with minor modifications
to the heat induced epitope retrieval timings. The
NCFAD laboratory subjected their slides to 25 min of
hydrated autoclaving greatly enhanced the specific
staining signals in their automated staining processes.
Since its initial use, individual laboratories have
introduced modifications to the generic protocol which,
in common with other commercial immunodetec-
tion systems, should be subject to proficiency test-
ing controlled by the appropriate BSE reference
laboratory.19
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a. Bovine Spongiform Encephalopathy Antigen Test Kit, Immu-
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c. FibroWax, Van Loenen Instruments, Zaandam, The Nether-
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d. ProbeOn Plus Slides, Fisher Scientific Company, Ottawa,
Ontario, Canada.
e. VECTABONDTM Reagent, Vector Laboratories, Burlingame,
CA.
f. Shandon CoverplateTM, Thermo Fisher Scientific Inc., Wal-
tham, MA.
g. Shandon SequenzaH Slide Rack, Thermo Fisher Scientific Inc.,
Waltham, MA.
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